Cystic fibrosis: ironing out the problem of infection?
Reid
David W
DW
Anderson
Gregory J
GJ
Lamont
Iain L
IL
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018441:Biofilms; D002478:Cells, Cultured; D018920:Coculture Techniques; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000235:genetics / Q000382:microbiology* / Q000473:pathology; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000096:biosynthesis* / Q000235:genetics; D004352:Drug Resistance, Microbial; D004847:Epithelial Cells / Q000378:metabolism / Q000382:microbiology* / Q000473:pathology; D006801:Humans; D007501:Iron / Q000378:metabolism*; D009154:Mutation; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D011550:Pseudomonas aeruginosa / Q000254:growth & development*; D020545:Respiratory Mucosa / Q000378:metabolism / Q000382:microbiology* / Q000473:pathology; D014031:Tobramycin / Q000494:pharmacology* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; C505032:CFTR protein, human; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D007501:Iron; D014031:Tobramycin